Clinical Trials Logo

SCLC, Extensive Stage clinical trials

View clinical trials related to SCLC, Extensive Stage.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05116007 Completed - Clinical trials for SCLC, Extensive Stage

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Start date: March 29, 2021
Phase: Phase 1
Study type: Interventional

Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.